VESTIGEConclusionsdupilumabasthmaNCT04400318type 2
…er time in patients with type 2, moderate-to-severe asthma from VESTIGEConclusions In patients with type 2, moderate-to-severe asthma, dupilumab s…
Entity family
Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.
This institution is selected. Its supporting articles are shown below.
…er time in patients with type 2, moderate-to-severe asthma from VESTIGEConclusions In patients with type 2, moderate-to-severe asthma, dupilumab s…